Verici Dx has reported a stronger start to 2026, with rising Tutivia test volumes and broader transplant centre adoption indicating that commercial momentum is building.
After more than five years of development work and steady progress since listing in December 2020, the company is now seeing clearer signs that healthcare providers are beginning to integrate its diagnostic offering into routine clinical decision-making. Diagnostics businesses tend to create the most value when adoption shifts from trial use to repeat ordering within established care pathways.
The latest numbers suggest that this transition may now be under way. Tutivia testing volumes rose 32 per cent quarter on quarter to 392 in Q1 2026, up from 296 in Q4 2025. On the basis of management’s indications, that equates to more than $0.9 million of revenue for the quarter and comes in comfortably ahead of expectations. For context, total Tutivia volumes in FY25 were 1,173, so the latest quarterly run rate implies a stronger commercial base heading into the new year.
The other important development is that adoption is broadening geographically and institutionally. Verici added seven new transplant centres during the quarter, taking its reach to around 20 per cent of US transplant activity, compared with 16 per cent in October 2025. That widening footprint is relevant because it expands the addressable base from which repeat demand can grow, while also helping validate the product with a larger set of clinical users.
Verici Dx Plc (LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests forming a kidney transplant diagnostics platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.
